{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T03:09:00Z","timestamp":1785380940515,"version":"3.55.0"},"reference-count":44,"publisher":"Japan Endocrine Society","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2007]]},"DOI":"10.1507\/endocrj.k06-069","type":"journal-article","created":{"date-parts":[[2007,12,19]],"date-time":"2007-12-19T05:49:39Z","timestamp":1198043379000},"page":"713-720","source":"Crossref","is-referenced-by-count":75,"title":["Prognostic Value of Thyrotropin Receptor Antibodies (TRAb) in Graves' Disease: A 120 Months Prospective Study"],"prefix":"10.1507","volume":"54","author":[{"given":"Carlo","family":"CAPPELLI","sequence":"first","affiliation":[{"name":"Department of Medical and Surgical Sciences, Internal Medicine and Endocrinology Unit, University of Brescia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"GANDOSSI","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, Internal Medicine and Endocrinology Unit, University of Brescia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"CASTELLANO","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, Internal Medicine and Endocrinology Unit, University of Brescia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"PIZZOCARO","sequence":"additional","affiliation":[{"name":"Department of Radiology, Spedali Civili of Brescia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"AGOSTI","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, Internal Medicine and Endocrinology Unit, University of Brescia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"DELBARBA","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, Internal Medicine and Endocrinology Unit, University of Brescia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilenia","family":"PIROLA","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, Internal Medicine and Endocrinology Unit, University of Brescia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira De","family":"MARTINO","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, Internal Medicine and Endocrinology Unit, University of Brescia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico Agabiti","family":"ROSEI","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, Internal Medicine and Endocrinology Unit, University of Brescia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Mckenna TJ (2001) Graves' disease. Lancet 357: 1793-1796.","DOI":"10.1016\/S0140-6736(00)04906-0"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Okamoto T, Iihara M, Obara T (2000) Management of hyperthyroidism due to Graves' and nodular disease. World J Surg 24: 957-961.","DOI":"10.1007\/s002680010167"},{"key":"3","unstructured":"3. Feldt-Rasmussen U, Glinoer D, Orgiazzi J (1993). Reassessment of antithyroid drug therapy of Graves' disease. Annu Rev Med 44: 323-334."},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200010263431707"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Toft AD, Weetman AP (1998) Screening for agranulocytosis in patients treated with antithyroid drugs. Clin Endocrinol (Oxf) 49: 271-282.","DOI":"10.1046\/j.1365-2265.1998.00583.x"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.52.493"},{"key":"7","unstructured":"7. Abraham P, Avenell A, Park CM, Watson WA, Bevan JS (2005). A systematic review of drug therapy for Graves' hyperthyroidism. Eur J Endocrinol 153: 489-498."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Levy EG (1997) Treatment of Graves' disease: The American Way. Baillieres Clin Endocrinol Metab 11: 585-595.","DOI":"10.1016\/S0950-351X(97)80798-7"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Vitti P, Rago T, Chiovato L, Pallini S, Santini F (1997) Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment. Thyroid 7: 369-375.","DOI":"10.1089\/thy.1997.7.369"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.1210\/jc.78.1.98"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Michelangeli V, Poon C (1998) The prognostic value of thyrotropin receptor antibody measurement in the early stages of treatment of Graves' disease with antithyroid drugs. Thyroid 8: 119-124.","DOI":"10.1089\/thy.1998.8.119"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Schleusener H, Schwander J, Fischer C, <i>et al.<\/i> (1989) Prospective multicentre study on the prediction of relapse after antithyroid drug treatment in patients with Graves' disease. Acta Endocrinol (Copenh) 120: 689-701.","DOI":"10.1530\/acta.0.1200689"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2001.01197.x"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1210\/jc.83.11.3777"},{"key":"15","unstructured":"15. Zweig MH, Campbell G (1993) Receiver-operating characteristic ROC plots: a fundamental evaluation tool in clinical medicine. Clin Chem 337: 1675-1681."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Hershman JM, Givens JR, Cassidy CE, Astwood EB (1966) Long-term outcome of hyperthyroidism treated with antithyroid drugs. J Clin Endocrinol Metab 26: 803-807.","DOI":"10.1210\/jcem-26-8-803"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Allannic H, Fauchet R, Orgiazzi J, Madec AM, Genetet B, Lorcy Y, Le Guerrier AM, Del ambre C, Derennes V (1990) Antithyroid drugs and Graves' disease: a prospective randomized evaluation of the efficacy of treatement duration. J Clin Endocrinol Metab 70: 675-679.","DOI":"10.1210\/jcem-70-3-675"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1998.00558.x"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1089\/105072502761016467"},{"key":"20","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2006.16.295"},{"key":"21","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-8981(00)00385-5"},{"key":"22","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1460173"},{"key":"23","doi-asserted-by":"publisher","DOI":"10.1055\/s-2004-814217"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Nordyke RA, Gilbert FI, Harada ASM (1988) Graves' disease. Influence of age on clinical findings. Arch Intern Med 148: 623-631.","DOI":"10.1001\/archinte.1988.00380030132023"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Aizawa T, Ishihiara M, Hashizume K, Takasu N, Yamada T (1989) Age-related changes of thyroid function and immunologic abnormalities in patients with hyperthyroidism due to Graves' disease. J Am Geriatr Soc 37: 944-948.","DOI":"10.1111\/j.1532-5415.1989.tb07279.x"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Benhaim Rochester D, Davies TF (2005) Increased risk of Graves' disease after pregnancy. Thyroid 15: 1287-1290.","DOI":"10.1089\/thy.2005.15.1287"},{"key":"27","doi-asserted-by":"publisher","DOI":"10.1210\/jc.85.3.1038"},{"key":"28","unstructured":"28. Weetman AP, Ratanachaiyavong S, Middleton GW (1986) Prediction of outcome in Graves' disease after carbimazole treatment. Q J Med 228: 409-419."},{"key":"29","unstructured":"29. Martino E, Pinchera A, Capiferri E (1988) Dissociation of responsiveness to thyrotropin-releasing hormone and thyroid suppressibility following antithyroid drug therapy of hyperthyroidism. J Clin Endocrinol Metab 3: 543-549."},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Clague R, Mukhtar ED, Pyle GA, <i>et al.<\/i> (1976) Thyroid stimulating immunoglobulins on the control of thyroid function. J Clin Endocrol Metab 43: 50-56.","DOI":"10.1210\/jcem-43-3-550"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Michico U, Satoshi I, Hideo S (2002) Thyroid specific T helper cell analysis by ELISPOT assay with thyrotropin receptor peptides. Peptides 23: 103-107.","DOI":"10.1016\/S0196-9781(01)00585-X"},{"key":"32","unstructured":"32. Al-Humaidi MA (2000) Serum cytokines levels in Graves' disease. Saudi Med J 21: 639-644."},{"key":"33","unstructured":"33. Bolanos F, Gonzalez-Ortiz M, Duron H, Sanchez C (2002) Remission of Graves' hyperthyroidism treated with methimazole. Rev Invest Clin 54: 307-310."},{"key":"34","unstructured":"34. Bojarska-Szmygin A, Janicki K, Pietura R, Janicka L (2003) The usefulness of thyroid size and TSH receptor antibody (TRAb) determinations in predicting the effectiveness of tiamazole and I-131 treatment for Graves-Basedow's disease. Ann Univ Mariae Curie Sklodowska [Med] 58: 242-247."},{"key":"35","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1999.00629.x"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Yamada T, Aizawa T (1994) Age-related therapeutic response to antithyroi drug in patients with hyperthyroid Graves' disease. J Am Geriatr Soc 42: 513-516.","DOI":"10.1111\/j.1532-5415.1994.tb04973.x"},{"key":"37","doi-asserted-by":"publisher","DOI":"10.1007\/s00595-005-3115-3"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Vaiana R, Cappelli C, Perini P, Pinelli D, Camoni G, Farfaglia R, Balzano R, Braga M (1999) Hyperthyroidism and concurrent thyroid cancer. Tumori 85: 247-252.","DOI":"10.1177\/030089169908500407"},{"issue":"6","key":"39","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1507\/endocrj1954.38.683","volume":"38","author":"TAJIRI J","year":"1991","ISSN":"https:\/\/id.crossref.org\/issn\/0013-7219","issn-type":"print"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Mussa GC, Corrias A, Silvestro L, Battan E, Mostert M, Mussa F, Pellegrino D (1999) Factors at onset predictive of lasting remission in pediatric patients with Graves' disease followed for at least three years. J Pediatr Endocrinol Metab 12: 537-541.","DOI":"10.1515\/JPEM.1999.12.4.537"},{"key":"41","doi-asserted-by":"publisher","DOI":"10.1089\/10507250152740966"},{"key":"42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199712043372307"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Saiki Y, Ishihara T, Ikekubo K, Mori T (2005) Differences in TSH receptor binding and thyroid-stimulating properties between TSH and Graves' IgG. Slowly-acting TSH receptor antibody moieties in Graves' sera affect assay data. Endocr J 52: 45-55.","DOI":"10.1507\/endocrj.52.45"},{"key":"44","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.K05-121"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/endocrj\/54\/5\/54_K06-069\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T06:43:48Z","timestamp":1618296228000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/endocrj\/54\/5\/54_K06-069\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.k06-069","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007]]}}}